Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 May 2018
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 May 2018 Planned End Date changed from 27 Jul 2020 to 27 Jul 2022.
- 05 May 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2022.